Evaluation of Novel Substituted Furopyridines as Inhibitors of Protein Kinases Related to Tau Pathology in Alzheimer´s Disease

Abstract

Background: Alzheimer´s disease (AD) is characterized by a progressive neuronal degeneration caused by two pathological hallmarks, hyperphosphorylated tau protein aggregated into tau filaments and amyloid precursor protein derived beta amyloid peptides aggregated into extracellular amyloid plaques. All attempts so far to find effective drugs failed in clinical trials. AD is a multifactorial disease, so that selective drugs to target one AD-relevant structure alone may not be sufficient. Objective: We built novel furopyridines with various substitution patterns to evaluate them as protein kinases inhibitors of enzymes related to tau pathology. Method: Furopyridine derivatives were synthesized and purified using column chromatography. The protein kinase inhibitory properties were determined in ATP-competition assays with determined affinity constants for the most active compounds. Results: The compounds were prepared in simple two-component reactions of substituted 1,4- dihydropyridines and respective quinones to obtain various substitutions of the molecular furopyridine scaffold. The substituent effects on the determined kinase inhibitory properties of cdk1, cdk2, Fyn, JNK3 and gsk-3β are discussed. Conclusion: Various 3-substitutions were found most sensitive for the protein kinase inhibition depending on the length, nature and a substituent positioning within. We identified compounds as inhibitors of several kinases as a tool to potentially combat the disease progress in a multitargeting approach.

MnO2-Mediated Oxidative Cyclization of “Formal” Schiff’s Bases: Easy Access to Diverse Naphthofuro-Annulated Triazines

“…Benzofuro-fused N-heterocycles are considered as common structural motifs in biologically active compounds, drug candidates and fluorescence materials ( Figure 1 ). For example, benzofuro [2,3- b ]pyridine, in particular Elbfluorene I , and its derivatives are important cyclin-dependent kinase inhibitors [ 17 , 18 , 19 , 20 ], the benzofuro [3,2- d ]pyrimidine derivative Amuvatinib II is a multitarget tyrosine kinase inhibitor [ 21 , 22 , 23 , 24 ], and benzofuro[2,3- b ]pyrazine III was designed as a deep-blue fluorescent emitter [ 25 ].…”